Tyra Biosciences reports Q2 net loss of $15.1M; FDA clears IND for TYRA-300

Tyra Biosciences, Inc.

2022-Q2 EPS reported -$0.72

Q2 2022 net loss $15.1M vs $5.5M in Q2 2021; R&D expense $12.0M vs $4.4M.
Cash and cash equivalents $275.1M as of June 30, 2022, sufficient to fund operations.
FDA cleared IND for TYRA-300 (FGFR3 inhibitor) to begin Phase 1/2 SURF301 study in metastatic urothelial carcinoma.
IND for TYRA-200 (FGFR2 inhibitor) on track for submission in 2H 2022 with initial focus on intrahepatic cholangiocarcinoma.
Key leadership hires: Sarah Honig (VP Corp Dev) and Ali Fawaz (General Counsel/Secretary).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.